Back to resources


September 9-13, 2023 | Vienna, Austria

Our CEO, Go van Dam, and CBO, Ari Aminetzah, will represent TRACER and participate in the one-on-one partnering meetings at the annual Congress of the European Association of Nuclear Medicine.

For you as a drug developer, this is a great chance to explore opportunities for fast-track clinical trials. Fill out the contact form on this page, to schedule your meeting.

We are excited to meet you in Vienna!

Phase 0 data points

We like to share the most important data points on Phase 0 clinical trials. In our meeting we will elaborate on this and there will be time to answer questions regarding clinical trials for your compound.

  • Approved method by FDA and EMA
  • Up to a 73% higher chance of success in subsequent trials
  • First patient in within 6 months
  • On- /off-target data in approximately 12 months
  • GLP material is sufficient
  • Only limited toxicity studies needed
  • Skip large animal studies
  • Significantly lower investment in comparison to Phase I

Fill out the form on this page to schedule your meeting at the EANM congres or send an e-mail to